HRP20110607T1 - Derivati tioksantena kao samostalna intiinfektivna sredstva namijenjena upotrebi u liječenju zaraznih bolesti - Google Patents
Derivati tioksantena kao samostalna intiinfektivna sredstva namijenjena upotrebi u liječenju zaraznih bolesti Download PDFInfo
- Publication number
- HRP20110607T1 HRP20110607T1 HR20110607T HRP20110607T HRP20110607T1 HR P20110607 T1 HRP20110607 T1 HR P20110607T1 HR 20110607 T HR20110607 T HR 20110607T HR P20110607 T HRP20110607 T HR P20110607T HR P20110607 T1 HRP20110607 T1 HR P20110607T1
- Authority
- HR
- Croatia
- Prior art keywords
- optionally substituted
- agent
- amino
- alkyl
- accordance
- Prior art date
Links
- 229960005475 antiinfective agent Drugs 0.000 title claims abstract 9
- 239000004599 antimicrobial Substances 0.000 title claims abstract 9
- 208000035473 Communicable disease Diseases 0.000 title claims abstract 4
- 238000011282 treatment Methods 0.000 title claims abstract 4
- PQJUJGAVDBINPI-UHFFFAOYSA-N 9H-thioxanthene Chemical compound C1=CC=C2CC3=CC=CC=C3SC2=C1 PQJUJGAVDBINPI-UHFFFAOYSA-N 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- -1 hydroxy, amino Chemical group 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 2
- 230000002924 anti-infective effect Effects 0.000 claims 2
- 244000052616 bacterial pathogen Species 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 244000053095 fungal pathogen Species 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 1
- 101100165225 Arabidopsis thaliana BETA-OHASE 2 gene Proteins 0.000 claims 1
- 125000005947 C1-C6 alkylsulfonyloxy group Chemical group 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 125000001769 aryl amino group Chemical group 0.000 claims 1
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000005241 heteroarylamino group Chemical group 0.000 claims 1
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 claims 1
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 1
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 claims 1
- 125000005419 heteroarylsulfonylamino group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 229940054058 antipsychotic thioxanthene derivative Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001484 phenothiazinyl group Chemical class C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 abstract 1
- 229940066767 systemic antihistamines phenothiazine derivative Drugs 0.000 abstract 1
- 150000005075 thioxanthenes Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dairy Products (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
Antiinfektivno sredstvo opće formule (I) naznačeno time štoW je C=CH; V se bira iz skupine koju čine S, SO2, SO, O ili NH; n je cijeli broj u rasponu od 1 do 6; svakog X se pojedinačno bira iz skupine koju čine vodik, halogen, hidroksi, amino, nitro, izborno supstituirani C1-6-alkil i izborno supstituirani C1-6-alkoksi; svakog od R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R13 i R14 se pojedinačno bira iz skupine koju čine vodik, halogen, hidroksi, amino, nitro, izborno supstituirani C1-6-alkil, izborno supstituirani C2-6-alkenil, izborno supstituirani C2-6-alkinil i izborno supstituirani C1-6-alkoksi, izborno supstituirani C2-6-alkeniloksi, karboksi, izborno supstituirani C1-6-alkoksikarbonil, izborno supstituirani C1-6-alkilkarbonil, formil, izborno supstituirani C1-6-alkilsulfonilamino, izborno supstituirani aril, izborno supstituirani ariloksikarbonil, izborno supstituirani ariloksi, izborno supstituirani arilkarbonil, izborno supstituirani arilamino, arilsulfonilamino, izborno supstituirani heteroaril, izborno supstituirani heteroariloksikarbonil, izborno supstituirani heteroariloksi, izborno supstituirani heteroarilkarbonil, izborno supstituirani heteroarilamino, heteroarilsulfonilamino, izborno supstituirani heterociklil, izborno supstituirani heterocikliloksikarbonil, izborno supstituirani heterocikliloksi, izborno supstituirani heterociklilkarbonil, izborno supstituirani heterociklilamino, heterociklilsulfonilamino, mono- i di(C1-6-alkil)amino, karbamoil, mono- i di(C1-6-alkil)aminokarbonil, amino-C1-6-alkil-aminokarbonil, mono- i di(C1-6-alkil)amino-C1-6-alkilaminokarbonil, C1-6-alkilkarbonilamino, amino-C1-6-alkilkarbonilamino, mono- i di(C1-6-alkil)amino-C1-6-alkilkarbonilamino, amin-C1-6-alkilamino, mono- i di(C1-6-alkil)amino-C1-6-alkilamino, cijano, gvanidino, karbamido, C1-6-alkanoiloksi, C1-6-alkilsulfonil, C1-6-alkilsulfinil, C1-6-alkilsulfoniloksi, aminosulfonil, mono- i di(C1-6-alkil) aminosulfonil, te izborno supstituirani C1-6-alkiltio; iR12 je vodik, hidroksi, amino, nitro, halogen, CH2Y, CHY2 i CY3, gdje se svaki Y pojedinačno bira između vodika, hidroksi, amino, nitro ili halogena; ili njegova sol, namijenjeno upotrebi u liječenju ili profilaksi zarazne bolesti koju uzrokuje uzročnik kojeg se bira između patogenih bakterija, gljivica i virusa, gdje se navedeno antiinfektivno sredstvo upotrebljava kao samostalno antiinfektivno sredstvo. Patent sadrži još 14 patentnih zahtjeva.
Claims (15)
1. Antiinfektivno sredstvo opće formule (I)
[image]
naznačeno time što
W je C=CH;
V se bira iz skupine koju čine S, SO2, SO, O ili NH;
n je cijeli broj u rasponu od 1 do 6;
svakog X se pojedinačno bira iz skupine koju čine vodik, halogen, hidroksi, amino, nitro, izborno supstituirani C1-6-alkil i izborno supstituirani C1-6-alkoksi;
svakog od R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R13 i R14 se pojedinačno bira iz skupine koju čine vodik, halogen, hidroksi, amino, nitro, izborno supstituirani C1-6-alkil, izborno supstituirani C2-6-alkenil, izborno supstituirani C2-6-alkinil i izborno supstituirani C1-6-alkoksi, izborno supstituirani C2-6-alkeniloksi, karboksi, izborno supstituirani C1-6-alkoksikarbonil, izborno supstituirani C1-6-alkilkarbonil, formil, izborno supstituirani C1-6-alkilsulfonilamino, izborno supstituirani aril, izborno supstituirani ariloksikarbonil, izborno supstituirani ariloksi, izborno supstituirani arilkarbonil, izborno supstituirani arilamino, arilsulfonilamino, izborno supstituirani heteroaril, izborno supstituirani heteroariloksikarbonil, izborno supstituirani heteroariloksi, izborno supstituirani heteroarilkarbonil, izborno supstituirani heteroarilamino, heteroarilsulfonilamino, izborno supstituirani heterociklil, izborno supstituirani heterocikliloksikarbonil, izborno supstituirani heterocikliloksi, izborno supstituirani heterociklilkarbonil, izborno supstituirani heterociklilamino, heterociklilsulfonilamino, mono- i di(C1-6-alkil)amino, karbamoil, mono- i di(C1-6-alkil)aminokarbonil, amino-C1-6-alkil-aminokarbonil, mono- i di(C1-6-alkil)amino-C1-6-alkilaminokarbonil, C1-6-alkilkarbonilamino, amino-C1-6-alkilkarbonilamino, mono- i di(C1-6-alkil)amino-C1-6-alkilkarbonilamino, amin-C1-6-alkilamino, mono- i di(C1-6-alkil)amino-C1-6-alkilamino, cijano, gvanidino, karbamido, C1-6-alkanoiloksi, C1-6-alkilsulfonil, C1-6-alkilsulfinil, C1-6-alkilsulfoniloksi, aminosulfonil, mono- i di(C1-6-alkil) aminosulfonil, te izborno supstituirani C1-6-alkiltio; i
R12 je vodik, hidroksi, amino, nitro, halogen, CH2Y, CHY2 i CY3, gdje se svaki Y pojedinačno bira između vodika, hidroksi, amino, nitro ili halogena;
ili njegova sol, namijenjeno upotrebi u liječenju ili profilaksi zarazne bolesti koju uzrokuje uzročnik kojeg se bira između patogenih bakterija, gljivica i virusa, gdje se navedeno antiinfektivno sredstvo upotrebljava kao samostalno antiinfektivno sredstvo.
2. Sredstvo namijenjeno upotrebi u skladu s patentnim zahtjevom 1, naznačeno time što R2 se bira iz skupine koju čine F, Cl, Br, I, CH2Y, CHY2 i CY3, gdje Y je atom halogena.
3. Sredstvo namijenjeno upotrebi u skladu s patentnim zahtjevom 2, naznačeno time što se svakog od R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R13 i R14 pojedinačno bira iz skupine koju čine vodik, izborno supstituirani C1-6-alkil i izborno supstituirani C1-6-alkoksi.
4. Sredstvo namijenjeno upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time što V je S ili SO.
5. Sredstvo namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time što n je cijeli broj u rasponu od 1 do 5.
6. Sredstvo namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačeno time što R12 se bira iz skupine koju čine vodik, CH3 i CH2OH.
7. Sredstvo namijenjeno upotrebi u skladu s patentnim zahtjevom 6, naznačeno time što W zajedno s funkcionalnom skupinom vezaom na sebi je CCH-(CH2)2-4-metilpiperazinil, CCH-CH2-CH(CH3)-4-metilpiperazinil, CCH-(CH2)2-piperazinil ili CCH-CH2-CH(CH3)-piperazinil.
8. Sredstvo namijenjeno upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva 1-7, naznačeno time što antiinfektivni spoj ima trans konfiguraciju.
9. Sredstvo namijenjeno upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva 1-7, naznačeno time što antiinfektivni spoj ima cis konfiguraciju.
10. Upotreba sredstva u skladu s bilo kojim od prethodnih patentnih zahtjeva 1-9, naznačena time što je navedeno sredstvo namijenjeno proizvodnji medikamenta za liječenje ili profilaksu zarazne bolesti koju uzrokuje uzročnik kojeg se bira između patogenih bakterija, gljivica i virusa, gdje se antiinfektivno sredstvo upotrebljava kao samostalno antiinfektivno sredstvo.
11. Upotreba according patentni zahtjev 10, naznačena time što se navedeno sredstvo upotrebljava ili primijenjuje u klinički relevantnoj količini.
12. Upotreba u skladu s patentnim zahtjevom 11, naznačena time što se navedeno sredstvo upotrebljava ili primijenjuje u klinički relevantnoj količini, čime se postiže koncentracija seruma u stabilnom stanju od manje od 20,0 mg/l.
13. Upotreba u skladu s patentnim zahtjevom 12, naznačen time što je navedena koncentracija seruma u stabilnom stanju u rasponu od 0,01 µg/l do manje od 20,0 mg/l.
14. Farmaceutski pripravak, naznačen time što sadrži sredstvo definirano u skladu s bilo kojim od patentnih zahtjeva 1-9 i u najmanju ruku jednu farmaceutski prihvatljivu podlogu ili pomoćna tvar, gdje navedeni pripravak ne sadrži dodatna antiinfektivna sredstva.
15. Farmaceutski pripravak u skladu s patentnim zahtjevom 14, naznačen time što je navedeni pripravak u obliku jedinice doziranja.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/DK2007/000006 WO2008080398A1 (en) | 2007-01-05 | 2007-01-05 | Anti - infective agents such as phenothiazine and thioxanthene derivates to treat infectious diseases |
| PCT/DK2008/000005 WO2008080408A1 (en) | 2007-01-05 | 2008-01-07 | Thioxanthene derivates usefulto treat infectious diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110607T1 true HRP20110607T1 (hr) | 2011-09-30 |
Family
ID=37914358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110607T HRP20110607T1 (hr) | 2007-01-05 | 2011-08-17 | Derivati tioksantena kao samostalna intiinfektivna sredstva namijenjena upotrebi u liječenju zaraznih bolesti |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100113430A1 (hr) |
| EP (2) | EP2301545A1 (hr) |
| JP (2) | JP5399921B2 (hr) |
| CN (1) | CN101594869B (hr) |
| AT (1) | ATE510540T1 (hr) |
| AU (1) | AU2008203743B2 (hr) |
| CA (1) | CA2673809C (hr) |
| CY (1) | CY1111778T1 (hr) |
| DK (1) | DK2114406T3 (hr) |
| EA (1) | EA016886B1 (hr) |
| ES (1) | ES2367151T3 (hr) |
| HK (1) | HK1139309A1 (hr) |
| HR (1) | HRP20110607T1 (hr) |
| MX (1) | MX2009007235A (hr) |
| NZ (1) | NZ577821A (hr) |
| PL (1) | PL2114406T3 (hr) |
| PT (1) | PT2114406E (hr) |
| WO (2) | WO2008080398A1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008080398A1 (en) * | 2007-01-05 | 2008-07-10 | Bkg Pharma Aps | Anti - infective agents such as phenothiazine and thioxanthene derivates to treat infectious diseases |
| EP2246349A1 (en) | 2009-04-20 | 2010-11-03 | BKG Pharma ApS | Treatment of infectious diseases |
| CN103172591B (zh) * | 2013-03-13 | 2014-07-30 | 陕西科技大学 | 含吩噻嗪基的Schiff碱类化合物及其制备方法和应用 |
| CN103709122B (zh) * | 2013-11-29 | 2016-05-25 | 四川大学 | 用于治疗的抗肿瘤和抗真菌化合物 |
| CA3028347A1 (en) * | 2016-06-23 | 2017-12-28 | Bioimics Ab | Anti-infective heterocyclic compounds and uses thereof |
| CN112353805A (zh) * | 2020-11-17 | 2021-02-12 | 北京化工大学 | 氟哌噻吨在治疗和预防柯萨奇病毒感染中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE578983A (hr) | 1958-05-29 | |||
| DE1518325B1 (de) | 1960-03-07 | 1970-08-27 | Smith Kline French Lab | Basisch substituierte Trifluormethylxanthene und deren nicht toxische Saeureadditionssalze und Verfahren zu deren Herstellung |
| GB1453828A (en) * | 1972-12-08 | 1976-10-27 | Kefalas As | Fluoro-substituted thiaxanthene derivatives |
| US4407800A (en) * | 1981-11-02 | 1983-10-04 | University Of Virginia Alumni Patents Foundation | Protozoacidal activity of phenothiazines |
| NZ228748A (en) * | 1988-04-20 | 1991-07-26 | Merrell Dow Pharma | Treating drug-resistant protozoal infections with a tricyclic compound and an antiprotozoal agent: composition and kit therefor |
| US20020151543A1 (en) * | 1998-05-28 | 2002-10-17 | Sepracor Inc. | Compositions and methods employing R (-) fluoxetine and other active ingredients |
| FR2813792B1 (fr) * | 2000-09-12 | 2003-03-14 | Inst Necker | Moyens pour la regulation des defenses immunitaires |
| US6569853B1 (en) | 2000-11-06 | 2003-05-27 | Combinatorx, Incorporated | Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders |
| CN101961317A (zh) | 2001-07-06 | 2011-02-02 | 生命周期药物公司 | 受控制的凝聚 |
| WO2003062388A2 (en) * | 2002-01-16 | 2003-07-31 | The Regents Of The University Of California | Inhibition of rna function |
| US20060193788A1 (en) * | 2002-11-26 | 2006-08-31 | Hale Ron L | Acute treatment of headache with phenothiazine antipsychotics |
| AU2003205543A1 (en) | 2003-01-14 | 2004-08-10 | Lifecycle Pharma A/S | Dry dispersions |
| KR20060066722A (ko) * | 2003-08-13 | 2006-06-16 | 쿠도스 파마슈티칼스 리미티드 | 아미노피론 및 ａｔｍ억제제로서의 이의 용도 |
| EA016803B1 (ru) * | 2004-04-30 | 2012-07-30 | Бкг Фарма Апс | Лечение инфекционных заболеваний |
| WO2006094207A2 (en) * | 2005-03-03 | 2006-09-08 | St. Jude Children's Research Hospital | Substituted phenoxazines and acridones as inhibitors of akt |
| WO2008080398A1 (en) * | 2007-01-05 | 2008-07-10 | Bkg Pharma Aps | Anti - infective agents such as phenothiazine and thioxanthene derivates to treat infectious diseases |
| EP2246349A1 (en) * | 2009-04-20 | 2010-11-03 | BKG Pharma ApS | Treatment of infectious diseases |
-
2007
- 2007-01-05 WO PCT/DK2007/000006 patent/WO2008080398A1/en active Application Filing
- 2007-01-05 MX MX2009007235A patent/MX2009007235A/es active IP Right Grant
-
2008
- 2008-01-07 DK DK08700129.3T patent/DK2114406T3/da active
- 2008-01-07 ES ES08700129T patent/ES2367151T3/es active Active
- 2008-01-07 EP EP10181816A patent/EP2301545A1/en not_active Withdrawn
- 2008-01-07 PL PL08700129T patent/PL2114406T3/pl unknown
- 2008-01-07 AT AT08700129T patent/ATE510540T1/de active
- 2008-01-07 PT PT08700129T patent/PT2114406E/pt unknown
- 2008-01-07 EP EP08700129A patent/EP2114406B1/en not_active Not-in-force
- 2008-01-07 CA CA2673809A patent/CA2673809C/en not_active Expired - Fee Related
- 2008-01-07 AU AU2008203743A patent/AU2008203743B2/en not_active Ceased
- 2008-01-07 NZ NZ577821A patent/NZ577821A/en not_active IP Right Cessation
- 2008-01-07 EA EA200970663A patent/EA016886B1/ru not_active IP Right Cessation
- 2008-01-07 CN CN2008800017965A patent/CN101594869B/zh not_active Expired - Fee Related
- 2008-01-07 JP JP2009544361A patent/JP5399921B2/ja not_active Expired - Fee Related
- 2008-01-07 WO PCT/DK2008/000005 patent/WO2008080408A1/en active Search and Examination
- 2008-01-07 US US12/522,163 patent/US20100113430A1/en not_active Abandoned
-
2010
- 2010-04-29 HK HK10104252.3A patent/HK1139309A1/xx not_active IP Right Cessation
-
2011
- 2011-08-17 HR HR20110607T patent/HRP20110607T1/hr unknown
- 2011-08-22 CY CY20111100800T patent/CY1111778T1/el unknown
-
2013
- 2013-04-03 JP JP2013077738A patent/JP2013173752A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2009007235A (es) | 2009-10-16 |
| EP2114406A1 (en) | 2009-11-11 |
| WO2008080408A1 (en) | 2008-07-10 |
| US20100113430A1 (en) | 2010-05-06 |
| JP5399921B2 (ja) | 2014-01-29 |
| NZ577821A (en) | 2012-07-27 |
| EA016886B1 (ru) | 2012-08-30 |
| JP2013173752A (ja) | 2013-09-05 |
| AU2008203743B2 (en) | 2012-07-12 |
| CN101594869A (zh) | 2009-12-02 |
| ES2367151T3 (es) | 2011-10-28 |
| EP2114406B1 (en) | 2011-05-25 |
| ATE510540T1 (de) | 2011-06-15 |
| PL2114406T3 (pl) | 2011-10-31 |
| EP2301545A1 (en) | 2011-03-30 |
| EA200970663A1 (ru) | 2009-12-30 |
| WO2008080398A1 (en) | 2008-07-10 |
| DK2114406T3 (da) | 2011-09-12 |
| AU2008203743A1 (en) | 2008-07-10 |
| CA2673809C (en) | 2013-08-13 |
| PT2114406E (pt) | 2011-08-25 |
| CA2673809A1 (en) | 2008-07-10 |
| HK1139309A1 (en) | 2010-09-17 |
| CN101594869B (zh) | 2013-08-07 |
| CY1111778T1 (el) | 2015-10-07 |
| JP2010514814A (ja) | 2010-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110607T1 (hr) | Derivati tioksantena kao samostalna intiinfektivna sredstva namijenjena upotrebi u liječenju zaraznih bolesti | |
| BR112022008919A2 (pt) | Composto e método para tratamento de distúrbios psiquiátrico ou neurológico | |
| CY1119261T1 (el) | Παραγωγα θειαζολιου | |
| JP2016530259A5 (hr) | ||
| HRP20110244T1 (hr) | Postupak liječenja raka | |
| AR026122A1 (es) | Derivados de 3(5)-amino-pirazol, procedimiento para su preparacion y su uso como agente antitumorales | |
| JP2015057437A5 (hr) | ||
| BRPI0413876A (pt) | tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos | |
| JP2008522981A5 (hr) | ||
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| MX2007004979A (es) | Derivados de indol tetraciclicos como agentes antiviricos. | |
| HRP20070505B1 (hr) | Spiro-oksindol spojevi i njihove upotrebe kao terapijska sredstva | |
| JP2019524883A5 (hr) | ||
| EA200600892A1 (ru) | Новые хинолиновые производные | |
| CY1107974T1 (el) | Παραγωγα κινολινης και κιναζολινης εχοντα συναφεια προς τους υποδοχεις τυπου 5ht1 | |
| CY1114803T1 (el) | Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης | |
| EA200500088A1 (ru) | Трициклические модуляторы ядерного рецептора стероидного гормона | |
| ECSP056195A (es) | Derivados de n-alquinil-2(ariloxi-sustituido)alquiltioamida como fungicidas | |
| JP2011219498A5 (hr) | ||
| EA200602130A1 (ru) | Замещенные арилацилтиомочевины и родственные соединения; ингибиторы репликации вирусов | |
| SI1427708T1 (sl) | Derivati amino-ftalazinona kot zaviralci kinaze, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo | |
| UY30411A1 (es) | Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
| CY1109880T1 (el) | ΑΝΤΑΓΩΝΙΣΤΗΣ CaSR | |
| JP2015025011A5 (hr) | ||
| JP2013513612A5 (hr) |